Patents Examined by Meera Natarajan
  • Patent number: 11608375
    Abstract: This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates (ADCs). In certain aspects, the anti-ASCT2 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects, the ASCT2-binding molecules bind specifically to cells expressing ASCT2, and in some instances, are internalized into the cells. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders characterized by ASCT2 overexpression, e.g., certain types of cancer. In a particular embodiment, the disclosure provides methods for treating cancer using ASCT2 ADCs.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: March 21, 2023
    Assignee: MedImmune, LLC
    Inventors: Nabendu Pore, Martin J. Borrok, III, Emil F. Michelotti, David A. Tice, Robert E. Hollingsworth, Chien-Ying Chang, Partha Chowdhury
  • Patent number: 11572410
    Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: February 7, 2023
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Carine Paturel, Nicolai Wagtmann
  • Patent number: 11572412
    Abstract: The present invention relates to anti-SIRP? (Signal regulatory protein alpha) antibodies and antigen-binding fragments thereof for therapeutic and diagnostic methods and compositions using them.
    Type: Grant
    Filed: June 2, 2022
    Date of Patent: February 7, 2023
    Assignees: Boehringer Ingelheim International GmbH, OSE Immmnotherapeatics SA
    Inventors: Pankaj Gupta, Priyanka Gupta, Habte Habtom, Yining Huang, Sandeep Kumar, Kathryn Phoenix, Kerry-Leigh Ralph, Wing Pan Kenny Tsang, Eduardo Sergio Trombetta
  • Patent number: 11525012
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: December 13, 2022
    Assignee: MedImmune Limited
    Inventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
  • Patent number: 11518813
    Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulator and/or components of the angiogenesis pathways and/or components of the TGF pathway are disclosed. Also disclosed is a method of treating proliferative disorders with the antitumor antagonists.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: December 6, 2022
    Inventors: Jackie Sheng, Bo Liu
  • Patent number: 11505602
    Abstract: Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM2 antibody or antigen binding fragment thereof.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: November 22, 2022
    Inventors: Michel Streuli, Venkataraman Sriram, Aritra Pal, Leonard G. Presta
  • Patent number: 11505604
    Abstract: This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: November 22, 2022
    Inventors: Xue-Ping Wang, Philip M. Arlen
  • Patent number: 11492414
    Abstract: Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In other embodiments, the monoclonal antibodies are chimeric, having the light and heavy chain variable regions of a non-human ERG antibody. Methods of using the antibodies to detect ERG, or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript, are also provided, including methods of detecting ERG or ERG fusion events in a clinical setting.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: November 8, 2022
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Shiv Srivastava, Shyh-Han Tan, Albert Dobi
  • Patent number: 11485783
    Abstract: Provided are antibodies or fragment thereof having binding specificity to the human GPRC5D protein. The antibodies or fragment thereof are capable of targeting cancer cells expressing GPRC5D, and thus can be used to treat the cancer, in particular hematological cancer.
    Type: Grant
    Filed: March 2, 2022
    Date of Patent: November 1, 2022
    Inventors: Runsheng Li, Wentao Huang
  • Patent number: 11485796
    Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: November 1, 2022
    Assignee: GENMAB A/S
    Inventors: Aran Frank Labrijn, Joyce I. Meesters, Joost J. Neijssen, Edward Norbert Van Den Brink, Janine Schuurman, Paul Parren
  • Patent number: 11479774
    Abstract: Provided herein are methods of treating a patient having a cancer that exhibits (i) a hemizygous loss of the TP53 gene; (ii) a hemizygous loss of the POLR2A gene; and/or (iii) a decreased level of expression of a POLR2A gene product relative to a reference (i.e., control) expression level. The methods comprise administering a therapeutically effective amount of a POLR2A inhibitor (e.g., a nucleic acid that inhibits the expression of a POLR2A protein, an amatoxin, alpha-amanitin, or alpha-amanitin conjugated to a cell targeting moiety, such as an EpCAM antibody) to a patient having or determined to have (i) a hemizygous loss of the TP53 gene; (ii) a hemizygous loss of the POLR2A gene; and/or (iii) a decreased level of expression of a POLR2A gene product relative to a reference (i.e., control) level.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: October 25, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Xiongbin Lu, Yunhua Liu
  • Patent number: 11472878
    Abstract: Methods are provided for treating a subject with an anti-CD47 agent.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: October 18, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Irving L. Weissman, Mark P. Chao, Ravindra Majeti, Jie Liu, Jens-Peter Volkmer
  • Patent number: 11466085
    Abstract: Provided in the present invention are a type of anti-human PD-L1 specific nanobodies and VHH chains thereof, coding sequences of the foregoing nanobodies or VHH chains thereof, corresponding expression vectors and host cells, and a method for producing antibodies.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: October 11, 2022
    Inventors: Hong Hoi Ting, Chung Lim Wong
  • Patent number: 11452775
    Abstract: This invention provides biomarkers (e.g., methylation of R198 or R200 of EGFR or the presence of an arginine at position 497 of EGFR) for the prediction of resistance to cetuximab therapy. This invention also provides methods for the selection of patients for combination therapy with cetuximab and PRMT inhibitors.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: September 27, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Mien-Chie Hung, Hsin-Wei Liao, Jung-Mao Hsu
  • Patent number: 11453716
    Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: September 27, 2022
    Inventors: Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Luke Evnin, Jeanmarie Guenot
  • Patent number: 11446328
    Abstract: It provides antibodies and chimeric antigen receptors (CARs) that specifically bind to an epitope containing N-acetyl-glucosamine and/or N-acetyl-galactosamine, e.g., expressed by a cancer cell or an inflammatory cell. Also provided are compositions including these antibodies and/or CARs, as well as polynucleotides, vectors, host cells, methods, and kits related thereto. Further provided are methods and kits for treating or preventing cancer in an individual by administering to the individual an antibody that specifically binds to an epitope containing N-acetylglucosamine or N-acetyl-galactosamine, or a T cell comprising a CAR that specifically binds to an epitope containing N-acetylglucosamine or N-acetyl-galactosamine, optionally in combination with another anti-cancer agent.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: September 20, 2022
    Inventor: Huiru Wang
  • Patent number: 11440962
    Abstract: The present disclosure provides isolated monoclonal anti-CD3epsilon antibodies or antigen-binding fragments thereof comprising one or more heavy chain CDR sequences selected from the group consisting of: SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 47, and/or one or more kappa light chain CDR sequences selected from the group consisting of: SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the use thereof.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: September 13, 2022
    Inventors: Jing Li, Qin Mei
  • Patent number: 11421028
    Abstract: The present invention provides multivalent and multispecific binding proteins that are capable of binding two or more antigens, or two or more epitopes. The present invention also provides methods of making and using such multivalent and multispecific binding proteins, including methods of using such binding proteins for prevention or treatment of various diseases, or for detecting specific antigens in vitro or in vivo.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: August 23, 2022
    Inventor: Chengbin Wu
  • Patent number: 11421030
    Abstract: This invention relates generally to antibodies or antigen binding fragments that bind to human B and T lymphocyte attenuator (BTLA) and uses thereof. More specifically, the invention relates to agonistic antibodies that bind human BTLA and modulate its activity, and their use in treating inflammatory, autoimmune and proliferative diseases and disorders.
    Type: Grant
    Filed: May 25, 2021
    Date of Patent: August 23, 2022
    Assignees: MiroBio Limited, Oxford University Innovation Limited
    Inventors: Simon John Davis, Richard John Cornall, Christopher Douglas Paluch
  • Patent number: 11421040
    Abstract: The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: August 23, 2022
    Assignee: Pfizer Inc.
    Inventors: Danielle Elizabeth Dettling, Yik Andy Yeung, Kristian Todd Poulsen, Veena Krishnamoorthy, Cesar Adolfo Sommer